Fastwave Medical

FastWave Medical is an emerging, award-winning player in the cardiovascular device space, specifically targeting the multi-billion dollar market for calcified artery disease with its advanced intravascular lithotripsy (IVL) platforms. The company has developed two distinct product lines: the FastWave Artero for peripheral artery disease (PAD) and the FastWave Sola for coronary artery disease (CAD), both designed to improve upon existing IVL technology with features like enhanced deliverability, predictable energy output, and user-friendly feedback. Having received notable industry accolades in 2025, FastWave appears to be in a late-stage development or early commercial preparation phase, backed by endorsements from key opinion leaders in interventional cardiology and vascular surgery. As a private company, its near-term trajectory will depend on successful regulatory clearance, market entry, and execution against established competitors.

Next-generation intravascular lithotripsy (IVL) platform utilizing sonic pressure waves (potentially laser-generated) to fracture arterial calcium. Designed with a focus on catheter deliverability in challenging anatomy, user-friendly procedural feedback, and predictable, durable energy output.

The IVL market is currently dominated by Shockwave Medical, now part of Johnson & Johnson, which has established strong clinical data, physician loyalty, and a large sales force. Other competitors include large device companies (Boston Scientific, Medtronic) with alternative calcium modification technologies (e.g., orbital atherectomy, scoring/cutting balloons) and potentially other IVL startups. FastWave must differentiate on technical performance (deliverability, consistency) and usability to compete effectively.